Kymera Therapeutics, Inc. (KYMR)
Company Info
| ISIN | US5015751044 |
|---|---|
| CUSIP | 501575104 |
| Sector | Healthcare |
| Industry | Biotechnology |
Highlights
| Market Cap | $2.05B |
|---|---|
| EPS | -$2.52 |
| Revenue (TTM) | $78.59M |
| Gross Profit (TTM) | -$117.42M |
| EBITDA (TTM) | -$163.46M |
| Year Range | $9.60 - $45.31 |
| Target Price | $51.36 |
| Short % | 17.79% |
| Short Ratio | 14.55 |
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Popular comparisons: KYMR vs. ARVN, KYMR vs. XBI
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Kymera Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Kymera Therapeutics, Inc. had a return of 42.34% year-to-date (YTD) and 19.56% in the last 12 months.
| Period | Return | Benchmark |
|---|---|---|
| Year-To-Date | 42.34% | 5.21% |
| 1 month | -8.07% | -4.30% |
| 6 months | 213.77% | 18.42% |
| 1 year | 19.56% | 21.82% |
| 5 years (annualized) | N/A | 11.27% |
| 10 years (annualized) | N/A | 10.33% |
Monthly Returns Heatmap
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | 28.75% | 30.26% | -5.85% | -16.37% | ||||||||
| 2023 | -16.04% | 77.89% | 22.64% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of KYMR is 57, suggesting that the investment has average results relative to the market in terms of risk-adjusted performance. This ranking is determined by the cumulative values of the indicators listed below.
Kymera Therapeutics, Inc.(KYMR)
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Kymera Therapeutics, Inc. (KYMR) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way.
Worst Drawdowns
The table below displays the maximum drawdowns of the Kymera Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Kymera Therapeutics, Inc. was 87.51%, occurring on Oct 27, 2023. The portfolio has not yet recovered.
The current Kymera Therapeutics, Inc. drawdown is 58.74%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -87.51% | Dec 29, 2020 | 713 | Oct 27, 2023 | — | — | — |
| -21.57% | Aug 31, 2020 | 7 | Sep 9, 2020 | 21 | Oct 8, 2020 | 28 |
| -14.49% | Aug 24, 2020 | 1 | Aug 24, 2020 | 3 | Aug 27, 2020 | 4 |
| -11.9% | Oct 20, 2020 | 2 | Oct 21, 2020 | 10 | Nov 4, 2020 | 12 |
| -10.81% | Nov 18, 2020 | 5 | Nov 24, 2020 | 5 | Dec 2, 2020 | 10 |
Volatility
Volatility Chart
The current Kymera Therapeutics, Inc. volatility is 16.92%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Income Statement
| TTM | |
|---|---|
| Revenue | |
Total Revenue | 0.00 |
Cost Of Revenue | 0.00 |
Gross Profit | 0.00 |
| Operating Expenses | |
Selling, General & Admin Expenses | 0.00 |
R&D Expenses | 0.00 |
Total Operating Expenses | 0.00 |
| Income | |
Income Before Tax | 0.00 |
Operating Income | 0.00 |
EBIT | 0.00 |
Earnings From Continuing Operations | 0.00 |
Net Income | 0.00 |
Income Tax Expense | 0.00 |
Interest Expense | 0.00 |
Other Non-Operating Income (Expenses) | 0.00 |
Extraordinary Items | 0.00 |
Discontinued Operations | 0.00 |
Effect Of Accounting Charges | 0.00 |
Non Recurring | 0.00 |
Minority Interest | 0.00 |
Other Items | 0.00 |